# AstraZeneca’s COVID-19 vaccine authorised for use in the EU

- Link: https://www.directorstalkinterviews.com/astrazenecas-covid-19-vaccine-authorised-for-use-in-the-eu/412957585
- Published: 2021-02-01T08:25:30+00:00
- Author: Amilia Stone

AstraZeneca’s COVID-19 vaccine has been granted a conditional marketing authorisation(
CMA) in the European Union (EU) for active immunisation to prevent COVID-19 caused
by SARS-CoV-2, in individuals 18 years of age and older.

Following review of the application, the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency based its positive opinion on data from
a rolling review of trial data from the primary analysis of the Phase III programme
led by the University of Oxford. Additional safety and efficacy data for the vaccine
will continue to accumulate from ongoing clinical trials and is expected to be published
in the coming weeks.

The CHMP recommends two doses of _COVID-19 Vaccine AstraZeneca_, formerly AZD1222,
to be administered at a four- to 12-week interval in people aged 18 years and older.
This dosing regimen was shown in clinical trials to be safe and effective in preventing
symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 
days after the second dose.

AstraZeneca is working with the EU following the approval of a CMA for active immunisation
to begin across member states.

> **Pascal Soriot, Chief Executive Officer, said: **“Today’s approval underscores
> the value of AstraZeneca’s COVID-19 vaccine, which is not only effective and well
> tolerated, but also easy to administer and, importantly, protects fully against
> severe disease and hospitalisations. We are deeply grateful to Oxford University,
> participants in the clinical trials and AstraZeneca colleagues for their unwavering
> commitment to providing this lifesaving vaccine to millions of Europeans.”

> **Professor Andrew Pollard, Director of the Oxford Vaccine Group and Chief Investigator
> on the Oxford vaccine trials, said:** “The approval by the European Commission
> is an important milestone in extending access to the Oxford/ AstraZeneca vaccine
> in our region and providing further endorsement that, after the rigorous scrutiny
> of regulators, the vaccine can be used to help protect populations from the coronavirus
> pandemic.”

AstraZeneca continues to work with regulatory authorities around the world to support
their ongoing rolling reviews for emergency supply or conditional approval during
the health crisis. AstraZeneca is also seeking Emergency Use Listing from the World
Health Organization for an accelerated pathway to vaccine availability in low-income
countries.

The vaccine can be stored, transported and handled at normal refrigerated conditions(
two-eight degrees Celsius/36-46 degrees Fahrenheit) for at least six months and 
administered within existing healthcare settings.

AstraZeneca continues to engage with governments, international organisations and
collaborators around the world to ensure broad and equitable access to the vaccine
at no profit for the duration of the pandemic.

Share on:
